Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: de Jong, Tamarah; Vosslamber, Saskia; Mantel, Elise; de Ridder, Sander; Wesseling, John; van der Pouw Kraan, Tineke; Leurs, Cyra; Hegen, Harald; Deisenhammer, Florian; Killestein, Joep; Lundberg, Ingrid; Vencovsky, Jiri; Nurmohamed, Mike; van Schaardenburg, Dirkjan; Bultink, Irene; Voskuyl, Alexandre; Pegtel, D.; van der Laken, Conny; Bijlsma, Johannes; Verweij, Cornelis
• Is Part Of: Arthritis research & therapy. Volume 18:Issue 1(2016)
• Page Start: 1
• Page End: 10
• Publication Date: 2016-12
• Subjects: Type I interferons -- Gene expression profiling -- Autoimmune diseases -- Rheumatic diseases -- Multiple sclerosis; Arthritis -- Periodicals; Arthritis -- Treatment -- Periodicals; 616.722005
• DOI: 10.1186/s13075-016-0946-9
• Languages: English
• ISSNs: 1478-6362

Abstract

Abstract Background Activation of the type I interferon (IFN) response program is described for several autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis (MS), myositis (IIM) and rheumatoid arthritis (RA). While IFNα contributes to SLE pathology, IFNβ therapy is often beneficial in MS, implying different immunoregulatory roles for these IFNs. This study was aimed to investigate potential diversification of IFNα-and IFNβ-mediated response programs in autoimmune diseases. Methods Peripheral blood gene expression of 23 prototypical type I IFN response genes (IRGs) was determined in 54 healthy controls (HCs), 69 SLE (47 test, 22 validation), 149 IFNβ-treated MS (71 test, 78 validation), 160 untreated MS, 78 IIM and 76 RA patients. Patients with a type I IFN signature were selected for analysis. Results We identified IFNα- and IFNβ-specific response programs (GC-A and GC-B, respectively) in SLE and IFNβ-treated MS patients. Concordantly, the GC-A/GC-B log-ratio was positive for all SLE patients and negative for virtually all IFNβ-treated MS patients, which was confirmed in additional cohorts. Applying this information to other autoimmune diseases, IIM patients displayed positive GC-A/GC-B log-ratios, indicating predominant IFNα activity. The GC-A/GC-B log-ratio in RA was lower and approached zero in part of the patients, implying relative importance of both clusters. Remarkably, GC-A/GC-B log-ratios appeared most heterogeneous in untreated MS; half of the patients displayed GC-A dominance, whereas others showed GC-B dominance or log-ratios near zero. Conclusions Our findings show diversification of the type I IFN response in autoimmune diseases, suggesting different pathogenic roles of the type I IFNs.